Output

List of VHPB publications online available

One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review
Andani A, van Damme P, Bunge EM, Salgado F, van Hoorn RC, Hoet B. Vaccine. 2022 Jan 21;40(2):196-205. doi: 10.1016/j.vaccine.2021.01.038. 
Epub 2021 Jan 30. PMID: 33526283.
Developing and Piloting a Standardized European Protocol for Hepatitis C Prevalence Surveys in the General Population (2016-2019).
Sperle I, Nielsen S, Bremer V, Gassowski M, Brummer-Korvenkontio H, Bruni R, Ciccaglione AR, Kaneva E, Liitsola K, Naneva Z, Parchemlieva T, Spada E, Toikkanen SE, Amato-Gauci AJ, Duffell E, Zimmerman R on behalf of the SPHERE-C Expert Group.
Front. Public Health, 28 May 2021; doi: 10.3389/fpubh.2021.568524
Many European countries ‘flying blind’ in their efforts to eliminate viral hepatitis.
Lazarus JV, Safreed-Harmon K, Colombo M, Reic T, Schatz E, Van Damme P; ACHIEVE Coalition.
Nat Rev Gastroenterol Hepatol. 2017 Jul 26;14(8):445-446. doi: 10.1038/nrgastro.2017.98.
Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response.
Mayorga O, Bühler S, Jaeger VK, Bally S, Hatz C, Frösner G, Protzer U, Van Damme P, Egger M, Herzog C.
J Infect Dis. 2016 Nov 15;214(10):1498-1506
Innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries: a roundtable meeting report.
David FitzSimons, Greet Hendrickx, Johannes Hallauer, Heidi Larson, Daniel Lavanchy, Ina Lodewyckx,Daniel Shouval, John Ward and Pierre Van Damme.
Hepatology, Medicine and Policy; 2016, 1:16. DOI 10.1186/s41124-016-0022-8
Editorial on “What is a potentially damaging vaccination delay in children younger than 2 years?”
Kane MA, Roudot-Thoraval F, Guerin N, Papaevangelou V, Van Damme P; Viral Hepatitis Prevention Board.
Hum Vaccin Immunother. 2016 Aug 2;12(8):2053-2056.
A hepatitis-free future: strategy first, then pricing.
Heidi Larson, Pierre Van Damme & David FitzSimons
Lancet Infect Dis & 2016, 16(4):399-400. doi: 10.1016/S1473-3099(16)00126-2.
Editorial on “What is a potentially damaging vaccination delay in children younger than 2 years?”
Mark A. Kane, Francois Roudot-Thoraval, Nicole Guerin, Vassiliki Papaevangelou, Pierre Van Damme & on behalf of the Viral Hepatitis Prevention Board
Human Vaccines & Immunotherapeutics 2016, DOI:10.1080/21645515.2016.1177689
Long-term Protection After Hepatitis B Vaccine
van Damme P
J Infect Dis. 2016, doi: 10.1093/infdis/jiv750
Prevalence of HBV and HCV among outpatients in the plovdiv region of Bulgaria,2010-2011
Kevorkyan A1, Teoharov P, Lernout T, Petrova N, Raycheva R, Ivanov I, van Damme P, Kojouharova M.
J Med Virol 2015,87: 401-406
A cohesive European policy for hepatitis B vaccination, are we there yet?
Lernout T, Hendrickx G, Vorsters A, Mosina L, Emiroglu N, Van Damme P.
Clin Microbiol Infect 2014,20 Suppl 5: 19-24
Viral Hepatitis Prevention B. Reduced prevalence of HBsAg variants following a successful immunization program in China.
Jilg W, Norder H, Kane M, Van Damme P, Vorsters A.
J Virol 2014, 88: 4605-4606
Incentives and barriers regarding immunization against influenza and hepatitis of health care workers.
Meeting report Barcelona
FitzSimons D, Hendrickx G, Lernout T, Badur S, Vorsters A, Van Damme P.
Vaccine 2014, 32: 4849-4854